Skip to main content

Table 5 Incidence rates per 100,000 person-years of malaria cases

From: Baseline incidence of meningitis, malaria, mortality and other health outcomes in infants and young sub-Saharan African children prior to the introduction of the RTS,S/AS01E malaria vaccine

  Kombewa, Kenya Kintampo, Ghana Navrongo, Ghana Overall
N = 1743 N = 3488 N = 1143 N = 6374
n PY Value (95% CI) n PY Value (95% CI) n PY Value (95% CI) n PY Value (95% CI)
Malaria
 Any 381 810 47,048 (42,442, 52,018) 1010 1714 58,928 (55,350, 62,678) 79 550 14,364 (11,372, 17,902) 1470 3074 47,824 (45,411, 50,333)
 Uncomplicated 364 810 44,949 (40,449, 49,812) 972 1714 56,711 (53,202, 60,392) 75 550 13,637 (10,726, 17,094) 1411 3074 45,905 (43,541, 48,364)
 Severe malaria 17 810 2099 (1223, 3361) 38 1714 2217 (1569, 3043) 4 550 727 (198, 1862) 59 3074 1919 (1461, 2476)
 Cerebral malaria 0 810 0 (0, 456) 1 1714 58 (1, 325) 0 550 0 (0, 671) 1 3074 33 (1, 181)
P. falciparum
 Uncomplicated 277 810 34,205 (30,296, 38,480) 813 1714 47,434 (44,229, 50,810) 74 550 13,455 (10,565, 16,891) 1164 3074 37,869 (35,725, 40,109)
 Severe 15 810 1852 (1037, 3055) 38 1714 2217 (1569, 3043) 4 550 727 (198, 1862) 57 3074 1854 (1405, 2403)
  1. According-to-protocol cohort, 5 to 17 months age-group N, Number of study participants at risk during a follow-up period of approximately 6 months after the 3rd virtual vaccine dose; n, number of cases reported during that follow-up period; PY: person-years; CI: confidence intervals
  2. Malaria cases were confirmed by rapid diagnostic test and/or microscopy